WuXi Healthcare Ventures and corporate-backed Deerfield Management are among the investors in the gene control drug developer's series C round.
US-based biopharmaceutical company Syros Pharmaceuticals has closed a $40m series C round featuring WuXi Healthcare Ventures, the corporate venturing unit of medical research company WuXi PharmaTech.
Investment firm Deerfield Management, Alexandria Venture Investments, the investment vehicle of life sciences real estate provider Alexandria, and financial services group Fidelity Management and Research also invested, alongside Casdin Capital, Polaris Partners, Redmile Group and Aisling Capital.
Syros is working on therapies that control gene expression to treat cancer and other serious diseases. The…
